Despite a challenging market backdrop fueled by geopolitical tensions and foreign fund outflows, five Indian sectors—Pharma, Energy, Defence, Capital Markets, and Metals—are hitting new 52-week highs even as the benchmark Nifty50 has fallen more than 7% during the same period. According to The Economic Times, these sectors are staging remarkable outperformance driven by structural earnings visibility and long-term growth tailwinds, indicating a fundamental shift beyond mere defensive plays. The Iran war, closure of the Strait of Hormuz, soaring crude prices above $100 per barrel, and a sharply weakening rupee have created one of the toughest backdrops for Indian equities in recent years. Foreign institutional investors have sold over $22 billion worth of Indian equities so far in 2026, already surpassing last year's $19 billion outflow and marking the deepest annual exodus in more than two decades.
Indian pharmaceutical companies are investing heavily in specialty drugs, biosimilars and local manufacturing in the US despite a near 10% fall in exports in FY26. According to Pharmexcil data, exports to the US stood at $9.47 billion in FY26, down 9.98% from the previous year. Namit Joshi, chairman of Pharmexcil, attributed the decline to 'high base effect, generic price erosion, inventory correction and product cycle timing' and emphasized it was 'not a structural concern'. The US remains the largest market with the ANDA pipeline intact and strong opportunities in specialty generics and injectables. Structural tailwinds continue to support the sector, with the domestic pharma market continuing to compound at around 10% while biosimilars and GLP-1 generics are opening entirely new profit pools for Indian drugmakers.
At Sun Pharma, the shift toward specialty medicines is already evident. Innovative Medicines is now the largest business in the US when compared to generics, according to Richard Ashcroft, CEO for North America. The company's global innovative medicines sales rose 20.1% during Q4FY26 and 16.8% for FY26, accounting for 22.2% of quarterly sales. Managing Director Kirti Ganorkar highlighted that 'Our US Innovative Medicines business has surpassed $1 billion in revenues'. Motilal Oswal noted that while US generics were affected by base portfolio price erosion, innovative medicines continued driving growth. The company is riding strong US generics momentum, rupee tailwinds and healthy domestic formulation growth, positioning it well for continued outperformance despite challenging market conditions.
Lupin reported one of the strongest US performances among Indian peers, with US business rising almost 40% year-on-year to $1.3 billion in FY26. CEO Vinita Gupta acknowledged that ''Our base business also grew this year, supported by higher volumes more than offsetting low-single-digit price erosion''. Instead of expanding conventional generics, the company plans more than 50 US launches over the next three years, including 10 first-to-file opportunities, four biosimilars and multiple 505(b)(2) products. Gupta emphasized the company's focus on 'doubling the share of complex products in our US business'. The company is benefiting from record order pipelines and India's accelerating push towards co-production and indigenisation, reflecting the broader structural growth story in defence sector.
Cipla is increasingly pursuing a 'manufacture closer to market' strategy, particularly in complex respiratory products. The company achieved approval for generic Ventolin, representing 'the first commercial MDI product to be manufactured from our US facility'. Managing Director Achin Gupta described this as 'an important strategic inflection point'. Cipla's US business posted annual revenue of $780 million in FY26, supported by differentiated products and stable base portfolio. Industry analysts noted this reflects how Indian drugmakers are investing in localised and technologically complex manufacturing capabilities rather than relying solely on commodity generic exports. The sector is backed by aggressive indigenisation policies, rising manufacturing capacities and strong long-term order visibility, positioning it well for sustained growth despite near-term volatility.
Zydus Lifesciences also sharpened focus on specialised therapies, with North America formulations business growing 5.3% sequentially in Q4FY26. The company filed two new 505(b)(2) dossiers in April and launched another rare disease therapy in the US market. Despite continued pricing pressure and competitive intensity, analysts say the US remains too large and profitable for Indian pharma firms to retreat from. As Joshi noted, 'India Pharma has moved beyond cost competitiveness' and is now competing on 'scale, reliability, science and strategic relevance'. The sector's margin expansion is increasingly becoming structural, driven more by improving product mix than simple operating leverage, with investors increasingly betting on the government's clear intent to build domestic defence capabilities while positioning India as a global export hub.
